Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7839044

[Gene therapy--basic principles].

H E Blum
View original source ↗Export metadata ↓

Abstract

Recombinant DNA technology allows the cloning of genes and their expression in vitro. Cloned genes are central to human gene therapy. The principle of gene therapy is based on three different strategies: gene replacement in classic genetic diseases which are caused by a single gene defect that conforms to the rules of Mendelian inheritance; gene augmentation for the treatment of complex genetic diseases by providing the cell with a new function; block of gene expression in acquired genetic diseases such as infections and malignancies.

Explore related subjects

DNA, RecombinantGene AmplificationGene Expression RegulationGenetic TechniquesGenetic TherapyHumansEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H E Blum. 1995-01-10. [Gene therapy--basic principles].. https://pubmed.ncbi.nlm.nih.gov/7839044/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

New multifunctional Escherichia coli-Streptomyces shuttle vectors allowing blue-white screening on XGal plates.

Four new shuttle vectors for Escherichia coli (Ec) and Streptomyces, pUWL218, pUWL219, pUWL-SK and pUWL-KS, which permit recognition of recombinant (re-) plasmids on XGal plates in Ec, were constructed. These vectors contain the replication functions of the Streptomyces wide-host-range multicopy plasmid pIJ101, the tsr gene conferring resistance to thiostrepton in Streptomyces, the ColEI origin of replication from the pUC plasmids for replication in Ec and the bla gene conferring resistance to ampicillin in Ec. They possess multiple cloning sites with a number of unique restriction sites and allow direct sequencing of re-derivatives using the pUC sequencing primers.

DNA, Recombinant↗
PubMed1995

[Factor VIII preparation produced by recombinant DNA-technology is approved in Norway].

Recombinant factor VIII (Baxter) is approved by the Norwegian Medicines Control Authority. The product represents an alternative to plasma-derived factor VIII in the treatment of patients with haemophilia A. Its use should be guided by clinical experts in care of haemophilia. Characterization studies of this and another recombinant factor VIII preparation have revealed no significant differences from plasma-derived factor VIII as regards biochemical and functional properties. Clinical studies have demonstrated similar in vivo recovery, plasma half-life and haemostatic activity as for plasma-derived factor VIII. Recombinant factor VIII should carry a low, if any, risk of transmitting blood-borne viruses pathogenic to man. The product includes pasteurized human albumin added as stabilizer, which has a well-documented safety record. There is no clear evidence of increased incidence of factor VIII inhibitors than with plasma-derived factor VIII. Further long-term surveillance studies are needed, however, to elucidate these matters.

DNA, Recombinant↗